Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 16,814 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Symptom Clusters Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Decision Support for PrEP

NCT05245201
View directory record Official record
Conditions
HIV Infections, Preexposure Prophylaxis (PrEP)
Interventions
Standard of care, Clinical decision support for PrEP
Other
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
15 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Ahoskie, North Carolina • Gastonia, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

NCT01089101
View directory record Official record
Conditions
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma, Refractory Neurofibromatosis Type 1, Refractory Visual Pathway Glioma
Interventions
Biospecimen Collection, Selumetinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Terminated Phase 3 Interventional Results available

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

NCT02772081
View directory record Official record
Conditions
Respiratory Distress Syndrome (RDS)
Interventions
LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube)
Combination Product · Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
30 Minutes to 24 Hours
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 25, 2026, 2:07 PM EDT
Completed No phase listed Observational

Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data

NCT05086081
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor 90mg, Prasugrel 10mg
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
28,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Positive Pressure Treatment of Obstructive Sleep Apnea

NCT00636181
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Auto AFlex, Auto CPAP, CPAP
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 25, 2026, 2:07 PM EDT
Terminated No phase listed Observational

Studying Fentanyl in Patients With Cancer

NCT00899951
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fentanyl citrate, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Oct 25, 2026, 2:07 PM EDT
Terminated Phase 2 Interventional Results available

GVAX vs. Placebo for MDS/AML After Allo HSCT

NCT01773395
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions
GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate
Biological · Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Studies of Elevated Parathyroid Activity

NCT00001277
View directory record Official record
Conditions
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
Interventions
68Ga-Dotatate, 18F-DOPA
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months and older
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

NCT04775953
View directory record Official record
Conditions
Staphylococcal Bacteraemia
Interventions
Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adapting the Finding Respect and Ending Stigma Around HIV (FRESH) Intervention for the Dominican Republic

NCT04491539
View directory record Official record
Conditions
Hiv
Interventions
Finding Respect and Ending Stigma around HIV (FRESH)
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
16 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Not applicable Interventional

Mobile Self-Management of Irritable Bowel Syndrome for Adolescents

NCT03138980
View directory record Official record
Conditions
Irritable Bowel Syndrome, Abdominal Pain
Interventions
BodiMojo Buddy for IBS
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 25, 2026, 2:07 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy

NCT07264270
View directory record Official record
Conditions
Lumbosacral Radicular Pain, Sciatic Radiculopathy, Sciatic Leg Pain, Sciatica, Lumbosacral Radicular Syndrome, Lumbosacral Radiculopathy
Interventions
C-1101, Placebo: Sterile Saline
Drug · Other
Lead sponsor
Consano Bio
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Fernandina Beach, Florida • Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Active, not recruiting Phase 2 Interventional

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

NCT05672173
View directory record Official record
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Ibrutinib, Lisocabtagene Maraleucel, Nivolumab, Pheresis, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Not applicable Interventional

ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit

NCT01270269
View directory record Official record
Conditions
Brain Injuries, Dementia, Myopathies, Muscle Disorders
Interventions
Behavioral: Physical and functional rehabilitation, Behavioral: Cognitive, physical, & functional rehabilitation
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 25, 2026, 2:07 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

SGA for TEE: Safe Alternative to Deep Sedation for Patients With High-risk Cardiopulmonary Disease.

NCT04939220
View directory record Official record
Conditions
Cardiopulmonary Disease
Interventions
TEE with SGA, TEE with Deep Sedation
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 25, 2026, 2:07 PM EDT
Active, not recruiting Phase 2 Interventional

Atrasentan in Patients With Proteinuric Glomerular Diseases

NCT04573920
View directory record Official record
Conditions
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
Interventions
Atrasentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Glendale, California • Los Angeles, California • San Dimas, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Paleolithic Diets vs T2D and Improvements in the Metabolic Syndrome

NCT00548782
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Paleolithic diet, ADA ( American Diabetes Association) recommended diet
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty

NCT06955923
View directory record Official record
Conditions
Trigger Point Pain, Myofascial
Interventions
Trigger point injection (lidocaine), Sham Comparator
Drug · Other
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
45 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fairfield, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Recruiting No phase listed Observational

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

NCT07652580
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Lymphoma Non-Hodgkin, B-cell Lymphoma, Immune Dysregulation
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
4 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Bethesda, Maryland • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 2 Interventional

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

NCT00006379
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

NCT05629962
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
Interventions
Bemnifosbuvir (BEM), Placebo
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Kingman, Arizona • Prescott, Arizona • Surprise, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 25, 2026, 2:07 PM EDT
Recruiting Phase 1 Interventional

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

NCT07224490
View directory record Official record
Conditions
Reproductive Disorder, Neurodegeneration, SARS-CoV 2, Long COVID
Interventions
Kisspeptin 112-121
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

NCT04375397
View directory record Official record
Conditions
CoronaVirus Induced Disease-2019 (COVID-19)
Interventions
Ibrutinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

NCT01885897
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma, Myeloma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML)
Interventions
ALT-803
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 25, 2026, 2:07 PM EDT